THE ANNUAL CONFERENCE OF THE
IsASL

Scientific Program

MARCH 15-17, 2012
THURSDAY 15.03.12 • 15:00-19:30

Chairmen: Prof. Ziv Ben Ari and Prof. Maurizia Brunetto

15:00-15:50
Round Table discussion – Difficult issues in the management of chronic HBV infection Q&A.

Prof. Maurizia Brunetto, University Hospital of Pisa, Italy

16:00-19:30

16:00-16:10 Opening, Prof. Ziv Ben Ari

16:10-17:10 HBV INFECTION: BASIC AND CLINICAL RESEARCH
Chairmen: Prof. Emanuel Sikuler, Dr. Shmuel Delgado

16:10-16:20 HBV induces its own coactivator PGC-1α via cellular oxidative stress.
Bar-Yishay I, Mouler Rechtman M, Halpern Z, Shlomai A. The Research Center for Digestive Tract and Liver Diseases, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

16:20-16:30 Hepatitis B surface antibody disappearance in pediatric liver transplanted patients.
Mozer-Glassberg Y1, Shamir R1, Mor E2, Steinberg R2, Silbermintz A3, Bergerin R1, Shapiro R1, 2. 1Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children’s Medical Center of Israel, Petach Tikva, 2,Sackler Faculty of Medicine, Tel-Aviv-University, Tel Aviv, 3Department of Transplantation, Rabin Medical Center, Petah-Tikva, 2Organ Transplant Unit, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel.

16:30-16:40 Chronic HBV Infection In Israel.
Zuckerman E, Rennert HS, Zuckerman S, Rennert G. Liver Unit and Department of Community Medicine and Epidemiology Carmel Medical Center and CHS National Cancer Center, Haifa, Israel.

16:40-17:10 HBsAg – A new role for an old marker. Prof. Maurizia Brunetto, University Hospital of Pisa, Italy.

17:10-17:30 Coffee break

17:30-18:30 LIVER RESECTION AND TRANSPLANTATION
Chairmen: Prof. Yaacov Baruch, Dr. Michal Carmiel-Haggai

17:30-17:40 Micromicrocapsules made of biosynthetic hydrogel scaffolds for intravascular liver tissue regeneration therapy. Nayshool O1, Carmel J1, Saadi T1, Arish A1, Brannik Z2, Mironi-Harpaz I2, Seliktar D1, Baruch Y1, 2. Liver Unit, 2Department of Surgery B, Rambam – Health Care Campus, 3Bruce Rappaport Faculty of Medicine, 2Department of Biomedical Engineering, Technion- Israel Institute of Technology, Haifa, Israel.
Reduced Hepatic Injury in Toll-Like Receptor 4–Deficient Mice Following D–galactosamine/ lipopolysaccharide–Induced Fulminant Hepatic Failure.

Ben Ari Z, Avlas O, Pappo O, Zilbermints V, Cheporko Y, Shainberg A, Sharon E, Grief F, Hochhauser E. 1Liver Institute, 2Department of Histopathology, 3Department of Surgery A, Beilinson Hospital–Rabin Medical Center, Petah Tiqwa, 4Liver and Cardiac Research Laboratory, Felsenstein Medical Research Center, Petah Tiqwa, 5Sackler School of Medicine, Tel Aviv University, 6Gonda (Goldschmied) Medical Diagnostic Research Center, The Mina & Everard Goodman Faculty of Life Sciences Bar–Ilan University, Ramat Gan, Israel.

HLA matching with liver transplantation outcome suggest NK role via HLA–Cw* alloantigens.

Bishara A, Haj-Yehya-Abu-Aita O, Safadi R. 1Tissue Typing Unit, 2Liver Unit, Gastroenterology Institute, Hadassah Medical Center, Jerusalem.


Unfolded Protein Response Activation during Liver Regeneration following two-thirds partial hepatectomy. Schiewitz V, Uzi D, Tirosh B, Shibolet O. Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Jerusalem, Israel. 2Liver Unit, Tel Aviv Sourasky Medical Center & Tel-Aviv University, Tel-Aviv, Israel.

Laparoscopic Hepatectomy – Pushing the Boundaries of Laparoscopic Surgery. Nachmany I, Goichman Y, Klausner JM, Ben-Haim M. Department of Surgery, Tel Aviv Sourasky Medical Center and The Sackler School of Medicine, Tel Aviv University.

First Israeli Laparoscopic Robotically assisted Left Liver Lobectomy. Solomonov E, Nesher E, Gourevich M, Aizner S, Shaharabani E, Mor E. Hepato – Pancreato–Biliary Surgery Unit and Department of Organ Transplantation Beilinson Campus, Rabin Medical Center. Petah Tiqwa, Israel.

LIVER INJURY AND CARCINOGENESIS

Chairmen: Prof. Rafi Bruck, Prof. Fred Konikoff

mTOR activation plays a critical role in regulating acetaminophen induced hepatotoxicity.

Dotan U, Schiewitz V, Tirosh B, Shibolet O. Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Jerusalem, Israel. 2Liver Unit, Tel Aviv Sourasky Medical Center & Tel-Aviv University, Tel-Aviv, Israel.

The effects of hepatic iron overload or deficiency in thioacetamide induced acute liver injury.

Ackerman Z, Pappo O, Link G, Maya K, Grozovski M. 1Departments of Medicine, Mount Scopus Campus and 2Pathology, Hadassah-Hebrew University Medical Center, 3Department of Human Nutrition
Low CYP1A2 Enzyme Activity Protects from Hepatic Iron Overload in Patients with \( \beta \)-Thalassemia. Nitzan I, Revel-Vilk S, Godfarb A, Ilan Y, Hemed N, Shluter E. Pediatric Gastroenterology Unit, Department of Pediatrics, Pediatric Pediatric Hematology-Oncology Department, Pediatric Hematology Department, Liver Unit, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.

The Role of the Unfolded Protein Response in Hepatic Carcinogenesis. Scaiewicz V, Nahmias A, Barda I, Parchack E, Tirosh B, Shibolet O. Liver Unit, Division of Medicine, Hadassah-Hebrew University Medical Center, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Jerusalem. Liver Unit, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.

Low Incidence of Liver Damage in Non Alcoholics High Risk Patients with Psoriasis Exposed to High Dose Methotrexate. Makhoul BF, Ella Veitsman, Michael Libes, Yaacov Baruch. Liver Unit, Rambam Health Care Campus, Haifa. Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.

FRIDAY 16.03.12 • 08:00-14:00

08:00 – 08:20
HCV CHALLENGES AND TREATMENT
Chairmen: Dr. Yoav Lurie and Dr. Mathias Carlibach

Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin. Shapira A, Shapira S, Gal-Tanamy M, Zemel R, Benhar I, Tur-Kaspa R. Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat-Aviv; Molecular Hepatology Research Laboratory, Felsenstein Medical Research Center, Petah Tikva; The Integrated Cancer Prevention Center, Tel Aviv Medical Center, Tel-Aviv; School of Medicine, Tel-Aviv University, Ramat-Aviv; Department of Medicine D and Liver Institute, Rabin Medical Center, Bellinson Campus, Petah Tikva, Israel.

HCV treatment results in liver transplant recipients, a single center experience. Mlynarsky L, Phillips A, Katz P, Ben-Chaim M, Carmiel-Haggai M, Shibolet O, Katchman H. Liver Unit, Department of Gastroenterology, Organ Transplantation Unit, Department of Surgery, Tel Aviv Sourasky Medical Center and The Sackler School of Medicine, Tel Aviv University, Tel-Aviv. Western Galilee Hospital, Naharia.
08:20-11:00  HCV MINI-SYMPOSIUM CHALLENGES IN USING NOVEL PROTEASE INHIBITORS.
Chairmen: Prof. Ziv Ben Ari, Prof. Ran Tur-Kaspa
08:20-08:50  Prof. Geoffrey Dusheiko, Royal Free Hospital London, UK.
   Integrating DAA Into the HCV Clinic. New Treatment Paradigms
08:50-09:10  Prof. Christoph Sarrazin, Goethe-University Hospital, Frankfurt am Main, Germany.
   Clinical application of response markers for HCV protease inhibitors based treatment
09:10-09:30  Prof. Daniel Shouval, Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem.
   How to manage adverse events of protease inhibitors based treatment and drug-drug interaction
09:30-09:50  Prof. Geoffrey Dusheiko, Royal Free Hospital London, UK.
   How to use PI inhibitors in challenging patients
09:50-10:10  Prof. Christoph Sarrazin, Goethe-University Hospital, Frankfurt am Main, Germany.
   Clinical importance of HCV resistant variants in patients receiving Protease inhibitors
10:10-10:30  Prof. Eli Zuckerman, Liver Unit, Carmel Medical Center, Haifa.
   Direct acting antivirals: The near future
10:30-10:40  Prof. Ziv Ben Ari, Liver Disease Center, Sheba Medical Center, Tel Hashomer, Ramat Gan.
   HCV Treatment - New Israeli Guidelines
10:40-11:00  Panel Discussion and Q&A
11:00-11:20  Coffee break

11:20-14:00  NONALCOHOLIC FATTY LIVER DISEASE FROM BASIC TO CLINIC
Chairmen: Prof. Zamir Halpern, Prof. Tzvi Ackerman
11:20-11:30  The role of Essential Fatty Acids (EFA) and r6 Desaturase and SCD-1 in intrauterine and early
   developmental programming of Non-Alcoholic Fatty Liver Disease (NAFLD) in adult rodents.
   Hollander K1, Tempel-Brami C3, Feinaru M1, Konikoff FM1,2, Leikin Frenkel A1, 1Research Laboratory for
   Gallstones and Liver Lipid Metabolism, Tel Aviv University, 2Institute of Gastroenterology and Hepatology,
   Meir Medical center, Kfar saba, Israel, and 3MRI unit, Tel Aviv University, Israel.
11:30-11:40  Oral administration of DT56a exerts a hepatoprotective effect and alleviates insulin resistance and
   fatty liver disease. Shabat Y, Lichtenstein Y, Zolotorov L, Ben Ya’acov A, Ilan I. Liver Unit, Hadassah
   Medical Center, Ein Kerem, Jerusalem, Israel.
11:40-11:50 Combination of Vitamin D with Sitagliptin/Metformin improve liver fat and Triglyceride content in mice with Fatty Liver Disease. Vintfield Y, Krichevsky I, Svela S, Grosowski M, Bar Guy N, Assy N. Liver Unit, Pathology department. Ziv Medical Center. Biotechnology, Ort Braude College. Faculty of Medicine, Bar- ilan university, Safed, Galilee, Israel.

11:50-12:00 Effects of Aramchol on liver fat content and metabolic parameters in patients with non-alcoholic fatty liver disease (NAFLD): Results of a Phase-II randomized clinical trial. Safadi R, Hadassah University Hospital Ein Kerem and Holy Family Hospital, Nazareth; Konikoff FM, Meir MC; Gilat T, GalmMed Medical Research; Angel J, GalmMed Medical Research; Rosenthal-Galili Z, GalmMed Medical Research; Zuckerman E, The Lady Davis Carmel MC; Abo Mouch S, Hillel Yafe MC; Fich A, Soroka University MC; Issachar A, Belinson Rabin MC; Sikuler E, Soroka University MC; Assy N, Ziv MC; Baruch Y, Rambam MC; Hershkovitz A, Meir MC; Lurie Y, The Tel Aviv Sourasky MC, Mahamid M, Holy Family Hospital, Nazareth, Graif M, Tel Aviv Sourasky MC; Stern N, Tel Aviv Sourasky MC; Blank A, The Tel Aviv Sourasky MC; Ben Ba’ashal D, Tel Aviv Sourasky MC; Zelber-Sagi S, Tel Aviv Sourasky MC; Oren R, Hadassah University Hospital Ein Kerem.

12:00-12:10 Non-alcoholic fatty liver disease (NAFLD) independently predicts type-2 diabetes and pre-diabetes during a seven-year prospective follow-up. Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Halpern Z, Santo E, Oren R. Dept. Gastroenterology, Tel Aviv Sourasky Medical Center, Tel-Aviv; School of Public Health, Haifa University, Haifa; The Sackler Faculty of Medicine Tel-Aviv University, Israel.

12:10-12:20 Low Vitamin D levels in Nonalcoholic Fatty Liver Disease associate with Insulin resistance and Liver Injury progression via immune NK mechanism. Mahmud M, Abdullah I, Ghanous R, Amer J, Doron S. The Liver Unit, Holy Family Hospital, Nazareth; Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem; Liver Unit, Gastroenterology Institute, Hadassah Medical Center, Jerusalem.

12:20-12:30 The effect of resistance training on non-alcoholic fatty liver disease (NAFLD) a randomized clinical trial. Buch A, Webb M, Yeshua H, Kiss O, Vaisman N, Fliss N, Halpern Z, Santo E, Oren R, Shibolet, Zelber-Sagi S, Dept. Gastroenterology, Tel Aviv Sourasky Medical Center, Tel-Aviv; The Sackler Faculty of Medicine Tel-Aviv University, School of Public Health, Haifa University, Haifa; Clalit Health Services Israel.

12:30-12:50 THE LORE OF THE LIVER
Chairman: Prof. Yaron Ilan

"The Lore of the Liver or Kol Hakaved L’Kol Hakaved", Prof. Adrian Rueben Division of Gastroenterology and Hepatology, Medical University of South Carolina, USA. Gastroenterology Institute, Hadassah Medical Center, Jerusalem.
12:50-14:00  LIVER FIBROSIS: BASIC AND CLINICAL RESEARCH
Chairmen: Prof. Ran Oren, Prof. Alex Fish

12:50-13:00  Sortilin,a new player in hepatic stellate cell activation and liver fibrosis. Hubel E, Zvibel I, Halpern Z, Bruck R. The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

13:00-13:10  The pro-fibrotic effects of pregnancy in a hepatic fibrosis mice model. Amer J, Grifal R, Abu-Tair I, Doron S, Mruwat R, Kasher C, El-Khatib A, Safadi R. Liver Unit, Gastroenterology Institute, Hadassah Medical Center, Jerusalem.

13:10-13:20  The effect of Parathyroid hormone related peptide (PTHrP) on liver fibrosis. Abramovitch S, Sharvit E, Ben Tov A, Weisman Y, Reif S. Pediatric gastroenterology, Tel-Aviv Sourasky Medical Center.

13:20-13:30  The inhibitory effect of ligands of nuclear receptors on hepatic stellate cell activation and proliferation is mediated by downregulation of cell cycle proteins. Sharvit E, Reif S, Abramovitch S, Halpern Z, Bruck R. Institute of Gastroenterology, and Dept. of Pediatrics, Tel Aviv Sourasky Medical Center, and The Sackler School of Medicine, Tel-Aviv University, Tel Aviv.

13:30-13:40  Hepatic 13 C-Methacetin Metabolism Correlates Well with the Hepatic Venous Pressure Gradient (HVPG) in Patients with Cirrhosis. Reuben A, Guggenheim G, Hershkowitz A, Ben Oren I, Ilan Y. 1Medical University of South Carolina, Charleston SC, USA; 2Liver Unit, Hadassah Medical Center, Ein Kerem, Jerusalem; 3Exalenz Bioscience Limited, Modi’in, Israel.

13:40-13:50  Liver fibrosis as measured by transient elastography gradually decreases during antiviral therapy in patients with hepatitis C virus (HCV). Rabinowitch I, Levit S, Zelber-Sagi S, Kutchman H, Webb M, Phillips A, Bruck R, Luria Y, Shibolet O. 1Liver Unit, Department of Gastroenterology, Tel-Aviv Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv University. 2Liver Unit, Digestive Diseases Institute, Shaarei Zedek Medical Center, the Hebrew University. Jerusalem Israel.

13:50-14:00  Business meeting